Dociparstat sodium
- Generic Name
- Dociparstat sodium
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 177021-00-0
- Unique Ingredient Identifier
- 4O75889WF4
- Associated Conditions
- -
- Associated Therapies
- -
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 27
- Registration Number
- NCT04389840
- Locations
- 🇺🇸
Advanced Pulmonary Research Institute/Wellington Regional Medical Center, Loxahatchee Groves, Florida, United States
🇺🇸William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸Augusta University, Augusta, Georgia, United States
Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 75
- Registration Number
- NCT02873338
- Locations
- 🇺🇸
Franciscan St. Francis Health, Indianapolis, Indiana, United States
🇺🇸Baylor Research Institute/Baylor Sammons Cancer Center/Baylor University Medical Center, Dallas, Texas, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 12
- Registration Number
- NCT02056782
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath